Novavax secures a licensing deal worth up to $1.2 billion with Sanofi for its COVID-19 vaccine, entailing a stake in Novavax valued
AstraZeneca announced on Tuesday its decision to initiate the global withdrawal of its COVID-19 vaccine, citing a surplus of available updated vaccines